Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesRepligen Licenses Patent Rights for Treatment of Bipolar Disorder
Repligen, 04/01/09
Repligen Corporation announced that it has exclusively licensed worldwide rights for the use of uridine in the treatment of patients with bipolar disorder from McLean Hospital. The use of uridine in the treatment of patients with bipolar disorder is currently the subject of a patent application and upon issue, the patent will remain in force until 2025 prior to any regulatory extensions. Under the terms of the license agreement, McLean will receive an upfront payment, development milestones and royalties upon successful commercialization of uridine for bipolar disorder.
Today in Licensure/Accreditation...keeping you current
Receive free subspecialty "5-minute updates" via email
The Joint Commission’s Hospital Accreditation Recognized by CMS
Joint Commission news, 12/03/09
Office Alley Gets EHNAC Accreditation
HealthDataManagement, 11/25/09
The Joint Commission Introduces Perinatal Care Core Measures
Joint Commission news, 11/24/09
Article Search
Sponsor